Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03722589 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP
A Phase 4 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 4
- Development phase
- 944
- Enrollment target
NCT03722589 is a Phase 4 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 944 participants.
The verdict
NCT03722589, a Phase 4 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 944 participants
- Enrollment target
Study Summary
This randomized, open-label trial will assess humoral and cell-mediated immune responses to cell culture-based and recombinant unadjuvanted quadrivalent influenza vaccines compared to conventional egg-based unadjuvanted quadrivalent standard dose (15µg of HA per strain) influenza vaccines among persons aged 18-64 years. The trial will be conducted at two sites in the United States during two influenza seasons (2018-19 and 2019-20). Stratified enrollment procedures will be used to enroll a mix of participants based on age.
Interventions
- BIOLOGICAL Fluzone
- BIOLOGICAL Flucelvax
- BIOLOGICAL Flublok
- BIOLOGICAL Fluarix
- BIOLOGICAL Fluzone High-Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 944 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03722589
The ClinicalTrials.gov registry entry for NCT03722589 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 944 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluzone is the first listed.
NCT03722589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03722589 about?
NCT03722589 is a clinical study titled "Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP". This randomized, open-label trial will assess humoral and cell-mediated immune responses to cell culture-based and recombinant unadjuvanted quadrivalent influenza vaccines compared to conventional egg-based unadjuvanted quadrivalent standard dose (15µg of HA per strain) influenza vaccines among pers...
What is the current status of trial NCT03722589?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 944 participants. The study started on 2018-09-12. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03722589?
The interventions under investigation include: Fluzone (BIOLOGICAL), Flucelvax (BIOLOGICAL), Flublok (BIOLOGICAL), Fluarix (BIOLOGICAL), Fluzone High-Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT03722589?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.